Human Serum Paraoxonase

General Pharmacology

Volumn 31, Issue 3, 1998, Pages 329-336

  Mackness, Bharti ^a   Durrington, Paul N ^a   Mackness, Michael I ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Coronary heart disease; Gulf War syndrome; Lipid peroxides; Organophosphates; Oxidation; Paraoxonase

Indexed keywords

ARYLESTERASE; HIGH DENSITY LIPOPROTEIN; INSECTICIDE; LIPID PEROXIDE; ORGANOPHOSPHATE;

AMINO ACID SUBSTITUTION; ATHEROSCLEROSIS; DRUG HYDROLYSIS; ENZYME ACTIVITY; ENZYME POLYMORPHISM; ENZYME SUBSTRATE COMPLEX; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; ISCHEMIC HEART DISEASE; PERSIAN GULF SYNDROME; PRIORITY JOURNAL; REVIEW;

ARTERIOSCLEROSIS; ARYLDIALKYLPHOSPHATASE; ESTERASES; GENOTYPE; GLYCOPROTEINS; HUMANS; LIPOPROTEINS, HDL; ORGANOPHOSPHORUS COMPOUNDS; POLYMORPHISM, GENETIC;

EID: 0032168831     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(98)00028-7     Document Type: Review

References (89)

1. Abbott C.A., Mackness M.I., Kumar S., Boulton A.J.M., Durrington P.N. Serum paraoxonase activity, concentration and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler. Thromb. Vasc. Biol. 15:1995;1812-1818.
2. Adkins S., Gan K.N., Mody M., La Du B.N. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase. glutamine or arginine at position 191, for the respective A or B allozymes Am. J. Hum. Genet. 52:1993;598-608.
3. Aldridge W.N. Serum esterases I. two types of esterase (A and B) hydrolysing p-nitrophenyl acetate propionate and butyrate and a method for their determination Biochem. J. 53:1953;110-117. a.
4. Aldridge W.N. Serum esterases II. an enzyme hydrolysing diethyl p-nitrophenyl phosphate (E600) and its identity with the A-esterase of mammalian sera Biochem J. 53:1953;117-124. b.
5. Antikainen M., Murtomäki S., Syvänne M., Pahlman R., Tahvanainen E., Jauhiainen M., Frick M.H., Ehnholm C. The Gln-Arg 191 polymorphism of human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J. Clin. Invest. 98:1996;883-885.
6. Blatter M.-C., James R.W., Messmer S., Barja F., Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-85. identity of K-85 with paraoxonase Eur. J. Biochem. 211:1993;871-879.
7. Blatter-Garin M.-C., Abbott C.A., Messmer S., Mackness M.I., Durrington P.N., Pometta D., James R.W. Quantification of human serum paraoxonase by enzyme-linked immunoassay. population differences in protein concentrations Biochem. J. 304:1994;549-554.
8. Blatter-Garin M.-C., James R.W., Dussoix P., Blanché H., Passa P., Froguel P., Ruiz J. Paraoxonase polymorphism Met-Leu 54 is associated with modified serum concentrations of the enzyme. J. Clin. Invest. 99:1997;62-66.
9. Bøg-Hansen T.C., Krog H.H., Back U. Plasma lipoprotein-associated arylesterase is induced by bacterial lipopolysaccharide. FEBS Lett. 93:1978;86-90.
10. Boman H. Cholinesterase, arylesterase and lipoprotein parameters in twins. Acta. Genet. Med. Gemellol. 29:1980;281-287.
11. Brealey C.J., Walker C.H., Baldwin B.C. A-esterase activities in relations to the differential toxicity of primiphos-methyl to birds and mammals. Pestic. Sci. 11:1980;546-554.
12. Clendenning J.B., Humbert R., Green E.D., Wood C., Traver D., Furlong C.E. Structural organization of the human PON1 gene. Genomics. 35:1996;586-589.
13. Costa L.G., Manzo L. Biochemical markers of neurotoxicity. research strategies and epidemiology applications Toxicol. Lett. 77:1995;137-144.
14. Davies H.G., Richter R.J., Keifer M., Broomfield C.A., Sowalla J., Furlong C.E. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat. Genet. 14:1996;334-336.
15. Don M.M., Masters C.J., Winzor D.J. Further evidence for the concept of bovine plasma arylesterase as a lipoprotein. Biochem. J. 151:1975;625-630.
16. Ecobichon D.J., Stephens D.S. Perinatal development of human blood esterases. Clin. Pharmac. Ther. 14:1973;41-47.
17. Gan K.N., Smolen A., Eckerson H.W., La Du B.N. Purification of human serum paraoxonase/arylesterase. Drug. Metab. Dispos. 19:1991;100-106.
18. Geldmacher V., Mallinckrodt M., Diepgen T.L. The human paraoxonase polymorphism and specificity. Toxicol. Environ. Chem. 18:1988;79-196.
19. Goldstein J.L., Brown M.S. The low-density lipoprotein pathway and its relation to atherosclerosis. Annu. Rev. Biochem. 46:1977;897-937.
20. Haley R.W., Kurt T.L. Self-reported exposure to neurotoxic chemical combinations in the Gulf War. a cross-section epidemiologic study JAMA. 277:1997;231-237.
21. Haley R.W., Hom J., Roland P.S., Bryan W.W., Van Ness P.C., Bonte F.J., Devous M.D., Matthews D., Fleckenstein J.L., Wians F.M., Wolfe G.I., Kurt T.L. Evaluation of neurologic function in Gulf War veterans. a blinded case-control study JAMA. 277:1997;223-230. b.
22. Haley R.W., Kurt T.L., Hom J. Is there a Gulf War syndrome? Searching for syndromes by factor analysis of symptoms. JAMA. 277:1997;215-222. a.
23. Hassett C., Richter R.J., Humbert R., Chapline C., Crabb J.W., Omiecinski C.J., Furlong C.E. Characterization of cDNA clones encoding rabbit and human serum paraoxonase. the mature protein retains its signal sequence Biochemistry. 30:1991;10141-10149.
24. Hegele R.A., Brunt J.H., Connelly P.W. A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. Arterioscler. Thromb. Vasc. Biol. 15:1995;89-95. a.
25. Hegele R.A., Brunt J.H., Connelly P.W. Multiple genetic determinants of variation of plasma lipoproteins in Alberta Hutterites. Artheroscler. Thromb. Vasc. Biol. 15:1995;861-871. b.
26. Hegele R.A., Connelly P.W., Hanley A.J.G., Sun F., Harris S.B., Zinman B. Common genomic variants associated with variation in plasma lipoproteins in young aboriginal Canadians. Arteriscler. Thromb. Vasc. Biol. 17:1997;1060-1066. a.
27. Hegele R.A., Connelly P.W., Scherer S.W., Hanley A.J.G., Harris S.B., Tsui L.-C., Zinman B. Paraoxonase-2 gene (PON2) G148 variant associated with elevated fasting plasma glucose in non-insulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 82:1997;3373-3377. b.
28. Herrmann S.M., Blanc H., Poirier O., Arveiter D., Luc G., Evans A., Marques-Vidal P., Bard J.M., Cambien F. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM study. Atherosclerosis. 12:1996;299-303.
29. Humbert R., Adler D.A., Distecke C.M., Hassett C., Omiecinski C.J., Furlong C.E. The molecular basis of the human serum paraoxonase activity polymorphism. Nat. Genet. 3:1993;73-76.
30. Hyde E.G., Carmichael W.W. Anatoxin-A(s), a naturally occurring organophosphate, is an irreversible active site-directed inhibitor of acetylcholinesterase (EC 3.1.1.7). J. Biochem. Toxicol. 6:1991;195-201.
31. Jordan-Starck T.C., Witte D.P., Aronow B.J., Harmony J.A.K. Apolipoprotein J. a membrane policeman? Curr. Opin. Lipidol. 3:1992;75-85.
32. Kelso G.J., Stuart W.D., Richter R.J., Furlong C.E., Jordan-Starck T.C., Harmony J.A.K. Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry. 33:1994;832-839.
33. Kitchen B.J., Masters C.J., Winzor D.J. Effects of lipid removal on the molecular size and kinetic properties of bovine plasma arylesterase. Biochem. J. 135:1973;93-99.
34. Klimov A.N., Gurevich V.S., Nikiforova A.A., Shatilina L.V., Kuzmin A.A., Plavinsky S.L., Teryukova N.P. Antioxidative activity of high-density lipoproteins in vivo. Atherosclerosis. 100:1993;13-19.
35. La Du B. N. (1992) Human serum PON1/arylesterase. In Pharmacogenetics of Drug Metabolism (Edited by Kalow W.), pp. 51-91. Pergamon Press, New York.
36. La Du B.N., Novais J. Human serum organophosphatase. biochemical characteristics and polymorphic inheritance Reiner E., Aldrige W.N., Hoskin F.C.G. Enzymes Hydrolysing Organophosphorus Compounds. 1989;41-52 Ellis-Horwood, Chichester.
37. Li W.F., Furlong C.E., Costa L.G. Paraoxonase protects against chlorpyrifos toxicity in mice. Toxicol. Lett. 76:1995;219-226.
38. Li W.F., Matthews C., Disteche C.M., Costa L.G., Furlong C.E. Paraoxonase (PON1) gene in mice. sequencing, chromosomal localisation and development expression Pharmacogenetics. 7:1997;137-144.
39. Liao W., Florén C.H. Hyperlipidaemic response to endotoxin. a part of the host defence mechanism Scand. J. Infect. Dis. 25:1993;675-682.
40. Mackness M.I. A-esterases. enzymes looking for a role? Biochem. Pharmac. 38:1989;385-390.
41. Mackness M.I., Durrington P.N. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis. 115:1995;243-253.
42. Mackness M.I., Walker C.H. Multiple forms of sheep serum A-esterase activity associated with the high-density lipoprotein. Biochem. J. 250:1988;539-545.
43. Mackness M.I., Hallam S.D., Peard T., Warner S., Walker C.H. The separation of sheep and human serum A-esterase activity into the lipoprotein fraction by ultracentrifugation. Comp. Biochem. Physiol. 83B:1985;675-677.
44. Mackness M.I., Arrol S., Durrington P.N. Substrate specificity of human serum paraoxonase. Biochem. Soc. Trans. 19:1991;304S. a.
45. Mackness M.I., Arrol S., Durrington P.N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 286:1991;152-154. b.
46. Mackness M.I., Harty D., Bhatnagar D., Winocour P.H., Arrol S., Ishola M., Durrington P.N. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis. 86:1991;193-199. c.
47. Mackness M.I., Abbott C.A., Arrol S., Durrington P.N. The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem. J. 294:1993;829-834. a.
48. Mackness M.I., Arrol S., Abbott C.A., Durrington P.N. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 104:1993;129-135. b.
49. Mackness M.I., Mackness B., Durrington P.N., Connelly P.W., Hegele R.A. Paraoxonase. biochemistry, genetics and relationship to plasma lipoproteins Curr. Opin. Lipidol. 7:1996;69-76.
50. Mackness B., Mackness M.I., Arrol S., Turkie W., Durrington P.N. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br. J. Pharmac. 112:1997;265-268. a.
51. Mackness M.I., Arrol S., Mackness B., Durrington P.N. The alloenzymes of paraoxonase determine the effectiveness of high-density lipoprotein in protecting low density lipoprotein against lipid-peroxidation. Lancet. 349:1997;851-852. b.
52. Mackness B., Hunt R., Durrington P.N., Mackness M.I. Increased immunolocalization of paraoxonase, clusterin and apolipoprotein AI in the human artery wall with progression of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 17:1997;1233-1238. c.
53. Mackness M.I., Mackness B., Arrol S., Wood G., Bhatnagar D., Durrington P.N. Presence of paraoxonase in human interstitial fluid. FEBS Lett. 416:1997;377-380. d.
54. Maury C.P., Junge W., Teppo A.M. Serum esterase activity in reactive sytemic amyloidosis and its relation to amyloid A degrading activity. J. Lab. Clin. Med. 104:1984;761-766.
55. McElveen J., Mackness M.I., Colley C.M., Peard T., Warner S., Walker C.H. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin. Chem. 32:1986;671-673.
56. Mueller R.F., Horning S., Furlong C.E., Anderson J., Giblett E.R., Motulsky A. Plasma paraoxonase polymorphism, a new enzyme assay. population, family, biochemical and linkage studies Am. J. Hum. Genet. 35:1983;393-408.
57. Navab M., Hama-Levy S., Van Lenten B.J., Fonarow G.C., Carelinez C.J., Castellani L.W., Brennan M.-L., La Du B.N., Lusis A.J., Fogelman A.M. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J. Clin. Invest. 99:1997;2005-2019.
58. Nisselbaum J.S. Statistical significance of paraoxonase activity in a control group of children and a group of children of parents who had early myocardial infarction. Clin. Chem. 33:1987;1496. (letter).
59. 192-Arg) is associated with coronary heart disease in Japanese non-insulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 82:1997;2257-2260.
60. Omura O. (1980) Serum-paraoxonase-polymorphisms in Japan. M.D. Thesis, University of Erlangen (Germany).
61. Owen J.S., Lorenz P., Betschart B. HDL particles as the trypanosome-killing factor in human serum. an exclusive or inconclusive role? Parasitol. Today. 12:1996;250-257.
62. Patel B.N., Mackness M.I., Harty D.W., Arrol S., Boot-Handford R.P., Durrington P.N. Serum esterase activities and hyperlipidaemia in the streptozotocin-diabetic rat. Biochim. Biophys. Acta. 1035:1990;113-116.
63. Playfer J.R., Eze L.C., Bullen M.F., Evans D.A.P. Genetic polymorphism and interethnic variability of plasma paraoxonase activity. J. Med. Genet. 13:1976;337-342.
64. Pond A.L., Chambers H.W., Chambers J.E. Organophosphate detoxication potential of various rat tissues via A-esterase and aliesterase activities. Toxicol. Lett. 78:1995;245-252.
65. Primo-Parma S.L., Sorenson R.C., Teiber J., La Du B.N. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics. 33:1996;498-509.
66. Ruiz J., Blanché H., James R.W., Blatter-Garin M.-C., Vaisse C., Charpentier G., Cohen N., Morabia A., Passa P., Froguel P. Gln-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet. 346:1995;869-872.
67. Saha N., Roy A.C., Teo S.H., Tay J.S.H., Ratnam S.S. Influence of serum paraoxonase polymorphism on serum lipids and lipoproteins. Clin. Genet. 40:1991;277-282.
68. Sanghera D.K., Saha N., Aston C.E., Kamboh M.I. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 17:1997;1067-1073.
69. Secchiero S., Mussap M., Zaninotto M., Bertorelle R., Burlina A. Serum arylesterase (paraoxonase) activity following myocardial infarction. Clin. Chim. Acta. 183:1989;71-76.
70. Serrato M., Marian A.J. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J. Clin. Invest. 96:1995;3005-3008.
71. Shih D.M., Gu L., Hama S., Xia Y.-R., Navab M., Fogelman A.M., Lusis A.J. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J. Clin. Invest. 97:1996;1630-1639.
72. Smith A.B., Esko J.D., Hajduk S.L. Killing of trypanosomes by the human haptoglobin-related protein. Science. 268:1995;284-286.
73. Smolen A., Eckerson H.W., Gan K.N., Hailat N., La Du B.N. Characteristics of the genetically determined allozymic forms of human serum paraoxonase/arylesterase. Drug Metab. Dispos. 19:1991;107-112.
74. Sorenson R.C., Primo-Parmo S.L., Camper S.A., La Du B.N. The genetic mapping and gene structure of mouse paraoxonase/arylesterase. Genomics. 30:1995;431-438. a.
75. Sorenson R.C., Primo-Parmo S.L., Kuo C.-L., Adkins S., Lockridge O., La Du B.N. Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. Proc. Natl. Acad. Sci. USA. 92:1995;7187-7191. b.
76. Suehiro T., Nakauchi Y., Yamamoto M., Arii K., Itoh H., Hamashige N., Hashimoto K. Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. Int. J. Cardiol. 57:1996;69-73.
77. Szabo I., Rona K., Czinner A., Gachalyi B., Kaldor A. Is paraoxon hydrolytic activity predictive of myocardial infarction? Clin. Chem. 33:1987;742-743. (letter).
78. Szafran Z., Nowak J., Szafran H., Janik A. Esterolytic activity of blood serum in infants with hypertrophic pyloric stenosis. J. Clin. Chem. Clin. Biochem. 17:1997;321-324.
79. The Iowa Persian Gulf Study Group Self-reported illness and health status among Gulf War veterans. a population based study JAMA. 277:1997;238-245.
80. Uriel A. Characterisation des cholinesterases et d'autres esterases carboxylique apres electrophorese et immunoelectrophorese en gleose I. applications a l'etude des esterases du serum humain normal Ann. Inst. Pasteur. 101:1961;104.
81. Van Lenten B.J., Hama S.Y., de Beer F.C., Stafforini D.M., McIntyre T.M., Prescott S.M., La Du B.N., Fogelman A.M., Navab M. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. J. Clin. Invest. 96:1995;2758-2767.
82. Vitarius J.A., Sultatos L.G. Kinetic mechanism of the detoxification of the organophosphate paraoxon by human serum A-esterase. Drug Metab. Dispos. 22:1994;472-478.
83. Vitarius J.A., Sultatos L.G. The role of calcium in the hydrolysis of the organophosphate paraoxon by human serum A-esterase. Life Sci. 56:1995;125-134.
84. Watson A.D., Berliner J.A., Hama S.Y., La Du B.N., Faull K.F., Fogelman A.M., Navab M. Protective effect of HDL associated paraoxonase. inhibition of biological activity of minimally oxidized low density lipoprotein J. Clin. Invest. 96:1995;2882-2891. a.
85. Watson A.D., Navab M., Hama S.Y., Sevanian A., Prescott S.M., Stafforini D.M., McIntyre T.M., La Du B.N., Fogelman A.M., Berliner J.A. Effect of platelet-activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J. Clin. Invest. 95:1995;774-784. b.
86. Weber W. W. (1995) Influence of heredity on human sensitivity to environmental chemicals. Environ. Mol. Mutagen. 25, (Suppl. 26), 102-114.
87. WHO (1986) Informal consultation on planning strategy for the prevention of pesticide poisoning. Geneva, 25-29. WHO/VBC/86.926. (WHO, Geneva).
88. WHO (1990). Public Health Impact of Pesticides Used in Agriculture. Geneva, WHO.
89. Yamasaki Y., Sahamoto K., Watada H., Kajimoto Y., Hori M. The Arg (192) isoform of paraoxonase with low sarin-hydrolysing activity is dominant in the Japanese. Hum. Genet. 101:1997;67-68.